When Washington cuts off access to the best AI: the case for equipping researchers with Charlie

What happened: a cut-off decided 8,000 km from your laboratories

The decision had nothing to do with a technical bug or an outage. It was an act of commercial and strategic policy, taken unilaterally by a foreign administration, with direct consequences for the daily work of European researchers. A private company had to carry out a government order within hours, with no meaningful notice for its customers outside the United States.

This precedent is not an isolated one. A few months earlier, OpenAI had already reserved its Life Sciences model (GPT-Rosalind) for its “US Enterprise” customers. The underlying logic is clear: cutting-edge artificial intelligence is becoming a national strategic asset, subject to the same kind of controls as dual-use technologies. For a European researcher, this means that access to the best tools can be conditioned, restricted or withdrawn according to interests that are not their own.

The risk does not stop at losing access. When your research data passes through US servers, it is subject to the CLOUD Act, which allows US authorities to demand access to data hosted by American companies, wherever it is physically located. Pre-publication data, confidential experimental results, clinical information: all critical assets exposed to a foreign jurisdiction.

“This decision reminds us that artificial intelligence is already a major issue of national sovereignty.” From left to right, the French political class reacted with one voice on the core finding: the urgent need to be independent and sovereign. The Anthropic suspension immediately entered the public debate, making European technological autonomy a shared priority.

Why Charlie and Emerit Science are the answer for European researchers

Charlie is the scientific AI agent developed by Emerit Science, a French company. It was designed from the outset for European researchers, clinicians and innovators—not adapted to their constraints after the fact, but built around them. Where US solutions expose their users to geopolitical risks, Charlie rests on a simple promise: your tools and your data remain under European jurisdiction and accessible, whatever decisions are made elsewhere.

Charlie's strength does not depend on a single model that a government could switch off. Its “agent” architecture orchestrates complex actions autonomously—searching, cross-referencing sources, synthesizing—and is not locked into a single provider. This technological independence is precisely what was missing for the laboratories that saw Claude Fable 5 disappear overnight.

Charlie connects researchers to the major scientific databases, with a preference for open sources: PubMed (35M+ articles), PMC (10M+ full texts), HAL (the open archive of French scientific output), GEO (6M+ genomic datasets) and Espacenet (140M+ patents)—with traceable citations (DOI, PMID, patent numbers) for full compliance with academic standards. Relying on open databases such as HAL guarantees lasting, sovereign access to knowledge, shielded from commercial restrictions. And all this within a sovereign framework, natively in French, with support that understands the European regulatory and scientific context.